Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Cephalon
gptkb:Actavis_Generics gptkb:Barr_Pharmaceuticals |
| gptkbp:CEO |
gptkb:Richard_Francis
|
| gptkbp:country |
gptkb:Israel
|
| gptkbp:foundedIn |
1901
|
| gptkbp:headquartersLocation |
gptkb:Petah_Tikva
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teva Group
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Tel_Aviv_Stock_Exchange
|
| gptkbp:market |
global
|
| gptkbp:notableProduct |
gptkb:Ajovy
gptkb:Austedo gptkb:Copaxone |
| gptkbp:numberOfEmployees |
about 37,000
|
| gptkbp:parentCompany |
gptkb:Teva_Pharmaceutical_Industries_Ltd.
|
| gptkbp:products |
generic drugs
specialty medicines |
| gptkbp:revenue |
$15.8 billion (2022)
|
| gptkbp:stockExchange |
gptkb:NYSE
|
| gptkbp:stockSymbol |
gptkb:TEVA
|
| gptkbp:website |
https://www.tevapharm.com/
|
| gptkbp:bfsParent |
gptkb:Teva_Pharmaceutical_Industries_Ltd.
|
| gptkbp:bfsLayer |
7
|